William Blair & Company
PRCT icon

William Blair & Company’s Procept Biorobotics PRCT Stock Holding History

William Blair & Company’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Buy
531,724
+207,789
+64% +$5.2M 0.03% 339
2026
Q1 		$8.1M Buy
323,935
+113,669
+54% +$3.2M 0.02% 396
2025
Q4 		$6.61M Sell
210,266
-456,176
-68% -$15.1M 0.02% 450
2025
Q3 		$23.8M Buy
666,442
+169,237
+34% +$7.73M 0.06% 214
2025
Q2 		$28.6M Buy
497,205
+26,919
+6% +$1.52M 0.08% 187
2025
Q1 		$27.4M Buy
470,286
+52,392
+13% +$3.58M 0.08% 189
2024
Q4 		$33.6M Sell
417,894
-8,019
-2% -$685K 0.1% 176
2024
Q3 		$34.1M Buy
425,913
+5,608
+1% +$398K 0.1% 164
2024
Q2 		$25.7M Sell
420,305
-9,488
-2% -$564K 0.08% 186
2024
Q1 		$21.2M Buy
+429,793
New +$20.5M 0.07% 206
2023
Q3 		– Sell
-10,820
Closed -$382K – 1833
2023
Q2 		$382K Buy
+10,820
New +$358K ﹤0.01% 1153

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

William Blair & Company's PRCT Position: Q2 2026 in Review

William Blair & Company increased its Procept Biorobotics (PRCT) stake by 64% in Q2 2026, buying an estimated $5.2M and bringing the position to 531,724 shares worth $12M. The position accounts for 0.03% of the portfolio, ranked #339.

William Blair & Company first reported a position in PRCT in Q2 2023 and has held it in 11 quarters since. The position peaked at $34.1M in Q3 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • William Blair & Company held 531,724 shares of Procept Biorobotics worth $12M as of Q2 2026.
  • William Blair & Company bought 207,789 Procept Biorobotics shares in Q2 2026, an estimated $5.2M.
  • Procept Biorobotics made up 0.03% of William Blair & Company's portfolio in Q2 2026, its #339 holding.
  • William Blair & Company first reported a position in Procept Biorobotics in Q2 2023 and has held it in 11 quarters since.
  • William Blair & Company's Procept Biorobotics position peaked at $34.1M in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.